Windlas Biotech IPO Live Subscription Status

Live subscription status across each investor category and analyst recommendations

Windlas Biotech IPO Subscription Status: FINAL

Windlas Biotech Limited, incorporated in 2001, is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue.

Investor CategoryQuotaSubscription
Institutional (QIB)50%24.40x
Non-Insti. (HNI)15%15.73x
Retail (RII)35%24.13x
Total Subscription100%22.39x

Windlas Biotech IPO Subscription: End of Day Update

DayDay 1Day 2Day 3
QIB0.00x0.04x 24.40x
HNI 0.34x 1.07x 15.73x
Retail 6.12x 13.27x 24.13x
Total 3.15x 6.92x 22.39x

Windlas Biotech IPO Subscription: Analyst Recommendations


“WBL is focusing on formulation CDMO and there is no peer company focusing solely on the CDMO model. At higher price band of Rs. 460, the company is demanding a P/E valuation of 26.6x (to its restated FY21 EPS of Rs. 17.3). Considering its return ratios and profitability, the issue seems to be fully priced. But factoring the growth drivers of the CDMO sector and opportunities available for the company, we assign a “Subscribe for Long Term” rating for the issue”

religare broking – SUBSCRIBE FOR LONG-TERM

“We believe the company is well placed to grab the opportunity arising from the industry given its strong product portfolio, relationship with its customers, R&D capabilities, and efficient & quality compliant manufacturing facilities. We have a positive view on the company from the long term perspective,”


“At the higher end of the price band, Windlas Biotech is priced at a P/E ratio of ~64 times FY21 EPS (on a fully diluted on post-issue basis). While the P/E looks stretched, businesses are being priced at expensive valuations in this IPO season, and Windlas Biotech is no exception. Given the company’s leadership position, strong growth in topline, and good growth runway, we remain positive on the long-term prospects of this issue,”

Windlas Biotech IPO Subscription: Key IPO Details

Issue Size₹401.54 Cr
Open Date04/08/2021
Close Date06/08/2021
Face Value₹10/- per Equity Share
IPO Price₹448 – ₹460
Lot Size30 shares
LotsMin 1 – Max 14

Windlas Biotech IPO Subscription: Financials

Revenue from Ops₹307.27 Cr₹328.85 Cr₹427.60 Cr
Profit before Excep*₹27.34 Cr₹32.13 Cr₹43.53 Cr
Profit after Tax63.82 Cr₹16.21 Cr₹15.57 Cr
EPS (Basic)38.618.908.70
*Tax and Exceptional Items
As of March 2020EPS (Avg*)P/E (Floor)P/E (Cap)
Based on basic EPS13.7532.5833.45
* Weighted Average for last 3 years

Windlas Biotech IPO: Comparison with listed industry peers

Based on RHP, there are no listed companies in India that engage in a business similar to that of this Company. Hence, it is not possible to provide an industry comparison in relation to the Company

Windlas Biotech IPO Subscription – FAQs

1. How to apply for Windlas Biotech IPO in the Retail Category?

A: An investor in the retail category may either apply through the UPI process via DEMAT account or the ASBA process via bank account

2. How to apply for Windlas Biotech in HNI Category?

A: An investor can apply in the HNI category only through the ASBA process via bank account

3. Where can I find the Red Herring Prospectus (RHP) details?

A: You can visit the NSE or SEBI website for these details. Alternately you can click here: RHP

Leave a Reply

nineteen − 19 =

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.